Institutional and Insider Ownership
24.2% of Longevity Health shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
ReShape Lifesciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.
Earnings & Valuation
This table compares ReShape Lifesciences and Longevity Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ReShape Lifesciences | $610,000.00 | 0.00 | -$81.15 million | N/A | N/A |
| Longevity Health | $1.05 million | 2.42 | -$10.37 million | N/A | N/A |
Longevity Health has higher revenue and earnings than ReShape Lifesciences.
Profitability
This table compares ReShape Lifesciences and Longevity Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ReShape Lifesciences | -668.58% | -163.22% | -52.10% |
| Longevity Health | -682.67% | N/A | -261.90% |
Summary
Longevity Health beats ReShape Lifesciences on 5 of the 8 factors compared between the two stocks.
About ReShape Lifesciences
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
About Longevity Health
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
